Search
Insulin glulisine
go.drugbank.com/drugs/DB01309ApprovedInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able … As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood.
Categories: Drugs Used in DiabetesProducts: Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen, APIDRA SOLOSTAR 100 UNITS/ML, SOLUTION FOR INJECTION IN A PRE-FILLED PENInfluenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14559ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzeTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzeRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileCarbamoylcholine
go.drugbank.com/drugs/DB00411ApprovedCarbamoylcholine was granted FDA approval on 28 September 1972.[L30245] … Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932.
Categories: Compounds used in a research, industrial, or household settingTetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Synonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrileCategories: Antivirals used in combination for the treatment of HIV infectionsXanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawn[L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing.